Biotech company Amgen is expected to award an estimated $30 million direct-to-consumer account to FCB Worldwide's FCB Healthcare, New York. FCB will handle creative and media for Neupogen, a drug that helps fight infection after chemotherapy. An Amgen spokesman said the company is in final talks with FCB. FCB declined to comment.
Copyright July 2000, Crain Communications Inc.